Summary & Overview
HCPCS J0799: FDA-Approved HIV Pre-Exposure Prophylaxis Drug
HCPCS Level II code J0799 identifies an FDA-approved prescription drug reserved exclusively for HIV pre-exposure prophylaxis (PrEP) and explicitly not for HIV treatment. Nationally, this code matters for pharmacy billing, payer coverage policies for PrEP, and public health efforts to prevent HIV transmission. Its presence as a not otherwise classified HCPCS entry signals a specific billing pathway when other product-specific codes are not applicable.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and payer considerations relevant to this drug's billing. The publication outlines typical benchmarks and coverage themes, highlights policy and claims-processing implications for outpatient pharmacies and clinic settings, and summarizes coding caveats tied to PrEP-only indication.
This national summary is intended for billing managers, pharmacy directors, and policy analysts seeking clarity on coding and payer coverage landscapes for PrEP medications billed under J0799. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0799 describes an FDA-approved prescription drug indicated only for HIV pre-exposure prophylaxis (PrEP) and specifically not for use as treatment of HIV, categorized as not otherwise classified. The code represents a pharmacy-administered prescription product used to reduce the risk of HIV acquisition in individuals at substantial risk.
Service Type: Pharmacy-dispensed prescription drug for HIV PrEP
Typical Site of Service: Outpatient retail or specialty pharmacy; may also be billed in clinic-administered infusion settings if applicable based on local payer rules
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A sexually active adult patient presents to an outpatient infectious disease, sexual health, or primary care clinic requesting HIV pre-exposure prophylaxis (PrEP). The patient undergoes initial screening including HIV antigen/antibody testing, renal function assessment (serum creatinine and eGFR), hepatitis B serology, and a sexual health risk assessment. After negative HIV testing and acceptable renal function, the clinician prescribes an FDA‑approved PrEP medication billed with J0799 for administration or supply per payer policy. Typical workflow includes counseling on adherence, counseling about sexually transmitted infection prevention, ordering baseline laboratories, scheduling follow-up visits at 1 month and then quarterly, and documenting medical necessity. Typical sites of service include outpatient clinic, sexually transmitted infection clinic, community health center, or specialty infectious disease clinic. Common patient scenario: a 28‑year‑old cisgender man who has sex with men, reports recent condomless receptive anal sex with partners of unknown HIV status, has negative HIV testing today, creatinine within normal limits, and requests PrEP initiation. The medication is dispensed or administered per facility process and billed as J0799 with applicable modifiers when required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard reporting |